全面准入？市场准入与卫生技术评估进展综述：第8部分。
Access in all areas? A round up of developments in market access and health technology assessment: part 8.
作者信息
Ramagopalan Sreeram V, Pannelay Annie Jullien
机构信息
Centre for Pharmaceutical Medicine Research, King's College London, SE1 9NH, UK.
ProductLife Group, 10 avenue de l'arche, 92400 Courbevoie, France.
出版信息
J Comp Eff Res. 2025 Aug;14(8):e250091. doi: 10.57264/cer-2025-0091. Epub 2025 Jun 17.
Abstract
In this update, we discuss the pricing paradox of combination therapies in health technology assessment; examine the Inflation Reduction Act's impact on pharmaceutical innovation and analyze the revised Dutch economic evaluation guidelines.
摘要
在本次更新中，我们讨论了卫生技术评估中联合疗法的定价悖论；研究了《降低通胀法案》对药物创新的影响，并分析了荷兰修订后的经济评估指南。
相似文献
1
Access in all areas? A round up of developments in market access and health technology assessment: part 8.
J Comp Eff Res. 2025 Aug;14(8):e250091. doi: 10.57264/cer-2025-0091. Epub 2025 Jun 17.
2
Access in all areas? A round up of developments in market access and health technology assessment: part 7.
J Comp Eff Res. 2025 Jun;14(6):e250043. doi: 10.57264/cer-2025-0043. Epub 2025 Apr 14.
3
Access in all areas? a round up of developments in market access and health technology assessment: part 4.
J Comp Eff Res. 2024 Jun;13(6):e240060. doi: 10.57264/cer-2024-0060. Epub 2024 Apr 22.
4
A Comparative Analysis of International Drug Price Negotiation Frameworks: An Interview Study of Key Stakeholders.
Milbank Q. 2024 Dec;102(4):1004-1031. doi: 10.1111/1468-0009.12714. Epub 2024 Sep 17.
5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 19.
J Comp Eff Res. 2025 Jul;14(7):e250063. doi: 10.57264/cer-2025-0063. Epub 2025 May 12.
6
Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch.
Value Health. 2024 Nov;27(11):1507-1514. doi: 10.1016/j.jval.2024.07.011. Epub 2024 Jul 31.
7
The New Dutch Guideline for Economic Evaluations in Healthcare: Taking the Societal Perspective to the Next Level.
Value Health. 2025 Jun;28(6):930-935. doi: 10.1016/j.jval.2025.03.002. Epub 2025 Mar 20.
8
Applying early health technology assessment (e-HTA) to inform investment in novel health technologies in the US.
Int J Technol Assess Health Care. 2025 Jul 8;41(1):e45. doi: 10.1017/S0266462325100275.
9
Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Cochrane Database Syst Rev. 2014 Oct 16;2014(10):CD005979. doi: 10.1002/14651858.CD005979.pub2.
10
Digital interventions in mental health: evidence syntheses and economic modelling.
Health Technol Assess. 2022 Jan;26(1):1-182. doi: 10.3310/RCTI6942.
本文引用的文献
1
Pricing combination products: not how but who?
Eur J Health Econ. 2025 Jun;26(4):537-540. doi: 10.1007/s10198-025-01773-8. Epub 2025 Apr 17.
2
Access in all areas? A round up of developments in market access and health technology assessment: part 7.
J Comp Eff Res. 2025 Jun;14(6):e250043. doi: 10.57264/cer-2025-0043. Epub 2025 Apr 14.
3
The Inflation Reduction Act's Impact Upon Early-Stage Venture Capital Investments.
Ther Innov Regul Sci. 2025 Jul;59(4):769-780. doi: 10.1007/s43441-025-00773-3. Epub 2025 Apr 13.
4
The need to consider market access for pharmaceutical investment decisions: a primer.
J Comp Eff Res. 2025 May;14(5):e250036. doi: 10.57264/cer-2025-0036. Epub 2025 Apr 4.
5
The New Dutch Guideline for Economic Evaluations in Healthcare: Taking the Societal Perspective to the Next Level.
Value Health. 2025 Jun;28(6):930-935. doi: 10.1016/j.jval.2025.03.002. Epub 2025 Mar 20.
6
An Attribution of Value Framework for Combination Treatments.
Value Health. 2025 Jan;28(1):72-80. doi: 10.1016/j.jval.2024.08.012. Epub 2024 Oct 29.
7
Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies.
Value Health. 2025 Jan;28(1):81-87. doi: 10.1016/j.jval.2024.07.019. Epub 2024 Aug 9.
8
Access in all areas? A round up of developments in market access and health technology assessment: part 2.
J Comp Eff Res. 2023 Dec;12(12):e230162. doi: 10.57264/cer-2023-0162. Epub 2023 Nov 2.
9
Challenges in valuing and paying for combination regimens in oncology: reporting the perspectives of a multi-stakeholder, international workshop.
BMC Health Serv Res. 2021 May 3;21(1):412. doi: 10.1186/s12913-021-06425-0.
Zotero 插件